WonBiogen Co Ltd

WonBiogen maintains a conservative capital structure with a debt-to-equity ratio of 0.21, significantly below the industry median of 0.45, indicating a strong equity position relative to its liabilities. The company's liquidity position is characterized by a current ratio of 2.25, suggesting it has sufficient short-term assets to cover its short-term obligations. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints.

Profitability metrics show a return on equity (ROE) of 3.25% and a return on assets (ROA) of 2.43%, both below the industry median of 5.1% and 3.8%, respectively. This suggests that WonBiogen is underperforming its peers in terms of asset and equity utilization efficiency. The company's operating margin of 16.7% is in line with the industry median, but its net margin of 15.0% is slightly below the median of 16.2%, indicating potential inefficiencies in cost management or tax optimization.

WonBiogen's revenue is concentrated in a single disclosed segment, with no geographic breakdown provided in the available data. This lack of diversification could expose the company to regional or sector-specific risks, particularly in the healthcare equipment and supplies market. The absence of segment or geographic detail limits the ability to assess exposure to high-growth or high-risk markets.

The company's growth trajectory is modest, with the outlook indicating a 2.1% increase in revenue for the current fiscal year and a 1.8% increase for the next fiscal year. These figures are below the industry median growth rate of 4.5%, suggesting that WonBiogen may be facing competitive pressures or market saturation. The company's capital expenditure of -275.3 million KRW indicates a reduction in investment, which could signal a strategic shift or a response to financial constraints.

Risk factors include a medium liquidity risk due to the negative net cash position after debt, and a low dilution risk as the company has not issued additional shares recently. The risk assessment also highlights the potential for dilution if the company accesses its shelf registration or engages in further equity financing, though no such activity has been disclosed in the latest filings. The absence of recent significant events or regulatory actions suggests a stable operational environment, but the lack of innovation or expansion plans could limit long-term growth.

Recent filings and transcripts do not indicate any material events or strategic shifts. The company's financial statements show consistent performance with no major deviations in operating cash flow or free cash flow. The absence of recent earnings calls or investor updates suggests a low level of market engagement, which could affect investor sentiment and stock volatility.

WonBiogen generated KRW 35.2 billion in revenue, representing a 15.8% year-over-year increase driven by strong operational performance.

Net income grew at a 19.9% compound annual growth rate over the last four years, reaching KRW 6.6 billion.

WonBiogen maintains a low debt-to-equity ratio of 0.21, which is below the cohort median of 0.20.

The firm demonstrates best-in-class cash conversion at 2.35, far exceeding the cohort median of 0.84.

The company faces medium liquidity risk, which could constrain its ability to meet short-term financial obligations.

WonBiogen carries medium credit risk, suggesting potential challenges in maintaining favorable borrowing terms or credit ratings.

Return on assets is low at 2.43%, reflecting limited efficiency in utilizing total assets to generate profit.

Revenue KRW 26.75B, +50,9% YoY; Operating income +142,7% YoY.

• ▍Revenue KRW 26.75B, +50,9% YoY
• ▍Operating income +142,7% YoY
• ▍Net income +547,6% YoY
• ▍Free cash flow +1,5% YoY
• ▍Net margin 12.0%